Alpha Healthcare Price, Forecast, Insider, Ratings, Fundamentals & Signals

Durham, n.c., aug. 26, 2021 (globe newswire) -- humacyte, inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the successful completion of its business combination (the “business combination”) with alpha healthcare acquisition corp. (nasdaq: ahac) (“ahac”), a special purpose acquisition company sponsored by constellation alpha holdings. the resulting combined company, humacyte, is expected to commence trading of its shares of common stock and warrants on the nasdaq global select market® under the ticker symbols "huma" and “humaw,” respectively, on august 27, 2021. the business combination was approved by ahac stockholders on august 24, 2021.

New york and durham, n.c., aug. 04, 2021 (globe newswire) -- alpha healthcare acquisition corp. (nasdaq: ahac) (“ahac”), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the securities and exchange commission ("sec") and set a date of august 24, 2021, for its special shareholder meeting (the “special meeting”) to vote on, among other items, the proposed business combination with humacyte, inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale.

Durham, n.c., march 05, 2021 (globe newswire) -- humacyte, inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (hav) for arteriovenous (av) access in hemodialysis have been accepted for oral presentation at the charing cross (cx) international symposium taking place virtually april 19-22, 2021. on february 17, 2021, alpha healthcare acquisition corp. (nasdaq: ahac) (“ahac”), a special purpose acquisition company, and humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million pipe financing agreement.

DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the successful completion of its business combination (the “Business Combination”) with Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company sponsored by Constellation Alpha Holdings. The resulting combined company, Humacyte, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Global Select Market® under the ticker symbols "HUMA" and “HUMAW,” respectively, on August 27, 2021. The Business Combination was approved by AHAC stockholders on August 24, 2021.

NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") and set a date of August 24, 2021, for its special shareholder meeting (the “Special Meeting”) to vote on, among other items, the proposed business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale.

Humacyte is set to go public via the special purpose acquisition company Alpha Healthcare Acquisition Corp (NASDAQ: AHAC) in a deal that values the company at around $800 million.  Humacyte founder and CEO Laura Niklason and Alpha Healthcare Acquisition CEO Rajiv Shukla appeared on Benzinga's YouTube show "SPACs Attack" for an exclusive interview Tuesday.

They could even deliver greater gains than just a 10-times return.

DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis have been accepted for oral presentation at the Charing Cross (CX) International Symposium taking place virtually April 19-22, 2021. On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.

Humacyte has a platform technology allowing for the mass production of human organs and blood vessels within a laboratory. Its products are superior as they can be stored for over a year, pose little to no infection risk, and will not be rejected by the immune system.

Feb.17 -- Dr. Laura Niklason, chief executive officer and founder of Humacyte, discusses the biotech company's decision to go public through a merger with Alpha Healthcare Acquisition Corp., a special purpose acquisition company (SPAC). She speaks on "Bloomberg Markets: The Close.

Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.